- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn | 4 | GlobeNewswire (USA) | ||
| 23.12. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.12. | Pelthos Therapeutics signs first commercial deal for molluscum treatment | 3 | Investing.com | ||
| 04.12. | Pelthos Therapeutics sichert sich ersten Vertriebsvertrag für Molluscum-Medikament | 1 | Investing.com Deutsch | ||
| 04.12. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% | 135 | GlobeNewswire (Europe) | ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new... ► Artikel lesen | |
| 25.11. | Pelthos Therapeutics stock initiated with Buy rating at Roth/MKM | 3 | Investing.com | ||
| 13.11. | Pelthos Therapeutics GAAP EPS of -$5.30 | 1 | Seeking Alpha | ||
| 13.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results | 126 | GlobeNewswire (Europe) | Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1... ► Artikel lesen | |
| 13.11. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer | 13 | Pharmaceutical Technology | ||
| 07.11. | Pelthos Acquires US Rights To Xepi, Secures $18 Mln Financing | - | RTTNews | ||
| 07.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing | 288 | GlobeNewswire (Europe) | Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMIXepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in... ► Artikel lesen | |
| 07.11. | Biofrontera Inc. announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M | 182 | GlobeNewswire (Europe) | Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further... ► Artikel lesen | |
| 07.11. | EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch | 2 | Benzinga.com | ||
| 07.11. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.10. | Pelthos Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | Pelthos rolls out Zelsuvmi with campaign aimed at moms who 'don't mess around' | 3 | FiercePharma | ||
| 09.10. | Pelthos launches Moms Against Molluscum campaign for skin infection | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,436 | +4,02 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| VALNEVA | 3,692 | +1,88 % | Morgen-Update: Valneva-Aktie zieht durch - kommt jetzt die große Rallye? | ||
| MAINZ BIOMED | 1,210 | -4,72 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,58 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| QIAGEN | 38,755 | -0,93 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| BIONTECH | 80,90 | +1,32 % | BIONTECH SE ADR: Eilmeldung am Abend - Kurszündung im Verborgenen? | ||
| RECURSION PHARMACEUTICALS | 4,125 | 0,00 % | Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? | ||
| AVIDITY BIOSCIENCES | 72,16 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PALISADE BIO | 2,480 | 0,00 % | Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug | ||
| EDGEWISE THERAPEUTICS | 24,620 | -6,60 % | Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy | - In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,38 | -1,24 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| NUVATION BIO | 9,060 | -3,67 % | Nuvation Bio to Participate in Upcoming Investor Conferences | Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief... ► Artikel lesen | |
| VERA THERAPEUTICS | 52,17 | -2,63 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,910 | -2,49 % | JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update | ||
| MINERALYS THERAPEUTICS | 36,825 | -0,85 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
Das Unternehmen PELTHOS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,33 % bei einem Aktienkurs von 26,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.